Views & Analysis What doctors say about EpiPen pricing The furore over Mylan’s ‘price gouging’ in relation to EpiPen in the US went global, thanks to social media.
News Mylan responds to price backlash with generic EpiPen Company launches cut-price generic alongside existing branded version
News Mylan and Biocon file Herceptin biosimilar in Europe First Herceptin biosimilar filed in EU, companies say.
News Clinton attacks Mylan over drug pricing Presidential hopeful criticises "outrageous" EpiPen price increase.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
